Knowledge of and opinions on HIV preexposure prophylaxis among front-line service providers at canadian AIDS service organizations

AIDS Research and Human Retroviruses

Volumn 29, Issue 9, 2013, Pages 1183-1189

  Senn, Heather ^a   Wilton, James ^b   Sharma, Malika ^a   Fowler, Shawn ^c   Tan, Darrell H S ^a,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b Canadian AIDS Treatment Information Exchange   (Canada)

^c Hassle Free Clinic   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CANADA; FEMALE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ONLINE MONITORING; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PROPHYLAXIS; REVIEW; WORK EXPERIENCE;

ADENINE; ADULT; ANTI-HIV AGENTS; CANADA; CHEMOPREVENTION; DEOXYCYTIDINE; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PERSONNEL; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; QUESTIONNAIRES;

EID: 84882946988     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0090     Document Type: Review

References (30)

1. Grant RM, Lama JR, Anderson PL, et al.: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-2599.
2. Baeten JM, Donnell D, Ndase P, et al.: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, et al.: Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423-434.
4. Van Damme L, Corneli A, Ahmed K, et al.: Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367:411-422.
5. Marrazzo J, Ramjee G, Nair G, et al.: Pre-exposure prophylaxis for HIV in women: Daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). In 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 2013. Abstract 26LB.
6. U.S. Food and Drug Administration: FDA approves first drug for reducing the risk of sexually acquired HIV infection. Available at http://fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm. Accessed January 28, 2013.
7. Interim guidance: Preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011;60:65-68.
8. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep 2012;61:586-589.
9. AIDS Healthcare Foundation: No Magic Pills. Available at http://nomagicpills.org/. Accessed January 28, 2013.
10. AIDS Vaccine Advocacy Coalition: Pre-Exposure Prophylaxis (PrEP). Available at: Www.avac.org/ht/d/sp/i/262/pid/262 Accessed January 28, 2013.
11. Feinberg J: Truvada PrEP: Why I Voted ''Yes.'' Ann Intern Med 2012;157:521-522.
12. Wood LV: Why I Voted ''No'' to Truvada PrEP. Ann Intern Med 2012;157:519-520.
13. Hosek SG: HIV pre-exposure prophylaxis diffusion and implementation issues in nonclinical settings. Am J Prev Med 2013;44:S129-132.
14. Wheelock A, Eisingerich AB, Gomez GB, Gray E, Dybul MR, and Piot P: Views of policymakers, healthcare workers and NGOs on HIV pre-exposure prophylaxis (PrEP): A multinational qualitative study. BMJ Open 2012;2:e001234.
15. Tripathi A, Ogbuanu C, Monger M, Gibson JJ, and Duffus WA: Preexposure prophylaxis for HIV infection: Healthcare providers' knowledge, perception, and willingness to adopt future implementation in the southern US. South Med J 2012;105:199-206.
16. Leonardi M, Lee E, and Tan DH: Awareness of, usage of and willingness to use HIV pre-exposure prophylaxis among men in downtown Toronto, Canada. Int J STD AIDS 2011; 22:738-741.
17. Holt M, Murphy DA, Callander D, et al.: Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men. Sex Transm Infect 2012;88:258-263.
18. Heffron R, Ngure K, Mugo N, et al.: Willingness of Kenyan HIV-1 serodiscordant couples to use antiretroviral-based HIV-1 prevention strategies. J Acquir Immune Defic Syndr 2012;61:116-119.
19. Guest G, Shattuck D, Johnson L, et al.: Acceptability of PrEP for HIV prevention among women at high risk for HIV. J Womens Health (Larchmt) 2010;19:791-798.
20. Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, and Piot PK: Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: A multinational study. PLoS One 2012;7:e28238.
21. Galea JT, Kinsler JJ, Salazar X, et al.: Acceptability of preexposure prophylaxis as an HIV prevention strategy: Barriers and facilitators to pre-exposure prophylaxis uptake among atrisk Peruvian populations. Int J STD AIDS 2011;22:256-262.
22. Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee SJ, and Leibowitz AA: Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care 2011;23:1136-1145.
23. Gostin LO and Kim SC: Ethical allocation of preexposure HIV prophylaxis. JAMA 2011;305:191-192.
24. Leibowitz AA, Parker KB, and Rotheram-Borus MJ: A US policy perspective on oral preexposure prophylaxis for HIV. Am J Public Health 2011;101:982-985.
25. Liu AY, Grant RM, and Buchbinder SP: Preexposure prophylaxis for HIV: Unproven promise and potential pitfalls. JAMA 2006;296:863-865.
26. Myers GM and Mayer KH: Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: Current considerations in light of new findings. AIDS Patient Care STDS 2011;25:63-71.
27. Nguyen VK, Bajos N, Dubois-Arber F, O'Malley J, and Pirkle CM: Remedicalizing an epidemic: From HIV treatment as prevention to HIV treatment is prevention. AIDS 2011;25:291-293.
28. Arnold EA, Hazelton P, Lane T, et al.: A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS One 2012;7:e40603.
29. U.S. National Institutes of Health: Bangkok Tenofovir Study. Available at http://clinicaltrials.gov/ct2/show/NCT001191 ?term =CDC+ 4370&rank = 1. Accessed January 28, 2013.
30. Canadian Public Health Association: Preparing Public Health for New HIV Prevention Technologies: A Road Map for Comprehensive Action in Canada, 2011; Available at http://cpha.ca/uploads/progs/infectious/npt-hiv-e.pdf. Accessed February 18, 2013.